Montserrat Vendrell

TL;DR: The ERS guidelines for the management of adult bronchiectasis describe the appropriate investigation and treatment strategies determined by a systematic review of the literature, using the GRADE approach to define the quality of the evidence and the level of recommendations.

TL;DR: There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis, and an expert conference was convened to develop a consensus definition for use in clinical research.

TL;DR: Assessment of etiology, symptoms, bronchial colonization and infection, respiratory function, inflammation, structural damage, nutritional status, and quality of life is recommended in order to assess severity and to monitor clinical course.

TL;DR: Priorities identified in this consensus statement provide the clearest possible roadmap towards improving the understanding of the disease and the quality of care for patients with bronchiectasis.

TL;DR: Residual levels of total IgG over 600 mg/dl may help prevent progression of lung damage in patients with CVID and levels of IgG, clinical manifestations and PFTs seem sufficient for routine follow-up.